ReviewCancer letters2016
Immunotherapy and tumor microenvironment.
Review in Cancer letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 2 syntheses or guidelines pooled it, 303 citations in OpenAlex.
- Pooled it
- Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis.Medicine · 2017Pooled it
- Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.Nature communications · 2021Trial
- Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities.Human vaccines & immunotherapeutics · 2026Article
- Mesoporous polydopamine nanoplatform enhances IL-2 immunotherapy for hepatocellular carcinoma via mild photothermal therapy and lactate regulation.Asian journal of pharmaceutical sciences · 2026Article
- Article
- Harnessing photodynamic therapy for programmed cell death: the central role and contributions of metal complexes as next generation photosensitizers.RSC medicinal chemistry · 2025Review
- BNIP3 is a key driver of breast cancer progression and a novel glycolysis-regulating biomarker.Scientific reports · 2025Article
- Exploring the therapeutic potential of human umbilical cord mesenchymal stem cells derived extracellular vesicles in cancer immunotherapy.Discover oncology · 2025Review
- Global research trends in liver regeneration and immunomodulation: A perspective from bibliometric analysis.Human vaccines & immunotherapeutics · 2025Article
- Utilizing a novel mitochondrial-related gene signature for predicting the prognosis and immunological impact in bladder cancer.Discover oncology · 2025Article
- Vascularized Tumor-on-a-Chip Model as a Platform for Studying Tumor-Microenvironment-Drug Interaction.Macromolecular bioscience · 2025Review
- Review
- Battlegrounds of treatment resistance: decoding the tumor microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Neutrophil Dynamics in Response to Cancer Therapies.Cancers · 2025Review
- Myeloperoxidase expressing tumor associated neutrophils are associated with worse prognosis in metastatic breast cancer patients.Scientific reports · 2025Article
- Label-Free Detection of Programmed Death-Ligand 1 for Prognosis Using a Truncated Aptamer and SYBR Green I.Journal of fluorescence · 2025Article
- G0S2: a potential target for NSCLC identified through prognostic models from multi-Omic analysis of regulatory T cell metabolic genes.NPJ precision oncology · 2025Article
- A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management.Journal of proteome research · 2025Review
- Helicobacter pylori is associated with less tumor-infiltrating lymphocytes and a poor prognosis in gastric cancer.BMC gastroenterology · 2025Article
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer patients that are much greater than conventional chemotherapy. However, such responses only occur in a relatively small fraction of patients. A positive response to immunotherapy usually relies on dynamic interactions between tumor cells and immunomodulators inside the tumor microenvironment (TME). Depending on the context of these interactions, the TME may play important roles to either dampen or enhance immune responses. Understanding the interactions between immunotherapy and the TME is not only critical to dissect the mechanisms of action but also important to provide new approaches in improving the efficiency of current immunotherapies. In this review, we will highlight recent work on how the TME can influence the efficacy of immunotherapy as well as how manipulating the TME can improve current immunotherapy regimens in some cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.